T2 Biosystems and Allergan collaborate to develop bacterial resistance panel

2 November 2016 (Last Updated November 2nd, 2016 18:30)

T2 Biosystems is collaborating with Allergan to develop a novel diagnostic panel to detect Gram-negative bacterial species and antibiotic resistance for patients with serious bacterial infections, including infections leading to sepsis.

T2 Biosystems is collaborating with Allergan to develop a novel diagnostic panel to detect Gram-negative bacterial species and antibiotic resistance for patients with serious bacterial infections, including infections leading to sepsis.

These products will boost T2 Biosystems’ sepsis line and include the first direct-from-blood diagnostic panel to detect antimicrobial resistance.

Due to repeated exposure, bacteria may develop resistance to antibiotics. This may lead to the survival of strains that cannot be treated by typical antimicrobial drugs.

"We hope not only to diagnose sepsis more quickly, but also enable the delivery of life-saving medicines more rapidly to the millions of patients at high-risk for bacterial infection."

A dangerous trend is resistance to a complete class of antibiotics known as carbapenems, because these are often the therapy of last resort for serious Gram-negative infections, according to the US Centers for Disease Control and Prevention (CDC).

T2 Biosystems’ bacterial resistance panel is being developed to particularly identify carbapenem resistance, which according to the CDC is a serious threat to public health.

T2 Biosystems president and chief executive officer John McDonough said: “Our initial sepsis products, the T2Candida and T2Bacteria Panels, are the first direct-from-blood sepsis diagnostics that provide species identification in an average of 4.3 hours while also detecting 40 percent or more infections that are completely missed by blood culture, which can take two to six days for results.

"By identifying resistant bacteria in the early hours of sepsis treatment, we can pick up another 10% or more of patients where providing the right antimicrobial drug to the patient may be further delayed, potentially saving more lives and significant costs to hospitals.

“We are pleased to be collaborating with Allergan, a company with significant expertise and leadership in treating patients with serious bacterial infections.

"Together, we hope not only to diagnose sepsis more quickly, but also enable the delivery of life-saving medicines more rapidly to the millions of patients at high-risk for bacterial infection.”

As per the terms of the agreement, Allergan will pay T2 Biosystems $4m in milestone payments with regard to the development of the bacterial resistance panel and an expansion of the T2Bacteria Panel currently under development.

T2 Biosystems will continue to have exclusive global distribution rights for all products developed through this partnership.

Allergan will have the option to cooperatively market T2 Biosystems’ menu of sepsis diagnostics to targeted hospitals across the world through its physician-facing institutional sales force.